• 1
    Palella FJ, Boyer RK, Moorman AC, Chmiel JS, Wood KC, Brook JT, Holmberg SD. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 2743.
  • 2
    Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Kuysz B, Dietrich M, Phillip AN, Lundgren JD. Decline in AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 229.
  • 3
    Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, Rosenthal E, Jougla E, Cacoub P, Salmon D, Chene G, Morlat P. Changes in cancer mortality among HIV-infected patients: the Mortalitè 2005 survey. Clin Infect Dis 2009; 48: 6339.
  • 4
    Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, Jougla E, Semaille C, Morlat P, Salmon D, Cacoub P, Chene G. Changes in causes of death among adults infected by HIV between 2000 and 2005: the Mortalitè 2000 and 2005 Survey (ANRS END19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48: 5908.
  • 5
    Little RF, Gutierrez M, Jaffe ES, Pau A, Mc Donald H, Wyndham W. HIV-associated non-hodgkin lymphoma: incidence, presentation and prognosis. JAMA 2001; 285: 18805.
  • 6
    Brodt HR, Kamps BS, Helm EB, Schafer H, Mitrov P. Kaposi's sarcoma in HIV infection: impact on opportunistic infections and survival. AIDS 1998; 12: 147581.
  • 7
    Tirelli U, Erranti D, Dolcetti R, Gloghini A, Serraino D, Vaccher E, Franceschi S, Baiocchi M, Carbone A. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol 1995; 13: 175867.
  • 8
    Biggar RJ, Engels EA, Ly S, Kahn A, Schymura MJ, Sackoff J, Virgo P, Pfeiffer RM. Survival after cancer diagnosis in patients with AIDS. J Acquir Immune Defic Syndr 2005; 39: 2939.
  • 9
    Chao C, Xu L, Abrams D, Leyden W, Horberg M, Towner W, Klein D, Tang B, Silverberg M. Survival of non Hodgkin Lymphoma in patients with or without HIV infection in the era of combined antiretroviral therapy. AIDS 2010; 24: 176570.
  • 10
    Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer 2009; 45: 93191.
  • 11
    Tsimberidou AM, Sarris AH, Medeiros LJ, Mesina O, Rodriguez MA, Hagemeister FB, Romaguera J, Pro B, McLaughlin P, Dang N, Cabanillas F. Hodgkin's disease in patients with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymph 2001; 41: 53544.
  • 12
    Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GO, Precone D, Gelatti U, Asensi V, Vaccher E. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. HIV HCC Cooperative Italian-Spanish Group. AIDS 2004; 18: 22852293.
  • 13
    Hoffmann C, Wolf E, Fatkenheuer G, Buhk T, Stoehr A, Plettenberg A, Stellbrink HJ, Jaeger H, Siebert U, Horst HA. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS related lymphoma. AIDS 2003; 17: 15219.
  • 14
    Vaccher E, Spina M. Talamini R, Zanetti M, di Gennaro G, Nasti G, Tavio M, Bernardi D, Simoncelli C, Tirelli U. Improvement of systemic human immunodeficiency virus-related non Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis 2003; 37: 155664.
  • 15
    Dupont C. Vasser E, Beauchet A, Aegert P, Berthè H, de Truchis P, Zucman D, Rouveix E, Saiag P. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. AIDS 2000; 14: 98793.
  • 16
    Hentrich M, Maretta L, Chow KU, Bogner JR, Schurmann D, Neuhoff P, Jager H, Reichelt D, Vogel M, Ruhnke M, Oette M, Weisse R, et al. Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol 2006; 17: 9149.
  • 17
    Hoffmann C, Chow KU, Wolf E, Faetkeneuer G, Stellbrink HJ, van Lunzen J, Jaeger H, Stoehr A, Plettenberg A, Wasmuth JC, Rockstroh J, Mosthaf F, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol 2004; 125: 45562.
  • 18
    Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005; 23: 44308.
  • 19
    Martin-Carbonero L, Palacios R, Valencia E, Saballs P, Sirera G, Santos I, Baldobi F, Alegre M, Goyenechea A, Pedreira J, Gonzales del Castillo J, Martinez-Lacasa J, et al. Long Term prognosis of HIV-infected patients with Kaposi's sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis 2008; 47: 4107.
  • 20
    Oehler-Janne C, Hughuet F, Prowencher S, Seifert B, Negretti L, Riener MO, Bonet M, Allal AS, Ciernik IF. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a Multicentric Cohort Study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 2008; 26: 25507.
  • 21
    Alfa-Wali M, Allen-Mersh T, Antoniou A, Tait D, Newsom-Davis T, Gazzard B, Nelson M, Bower M. Chemoradiotherapy for anal cancer in HIV-patients causes prolonged CD4 cell count suppression. Ann Oncol 2011 doi: 10.1093/annonc/mdr050.
  • 22
    1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Reccomm Rep 1992; 41: 119.
  • 23
    Sgadari C, Monini P, Barillari G, Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol 2003; 4: 53747.
  • 24
    Xicoy B, Ribera JM, Miralles P, Berenguer J, Rubio R, Mahillo B, Valencia ME, Abella E, Lopez-Guillermo A, Sureda A, Morgades M, Navarro JT. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage of immunodeficiency related Hodgkin lymphoma. Haematologica 2007; 92: 1918.
  • 25
    Crum-Cianflone N, Huppler Hullsiek K, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Agan BK, Wegner S. Trends in incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20 year cohort study. AIDS 2009; 23: 4150.
  • 26
    Diamond C, Taylor TH, Aboumrad T, Anton-Culver H. Changes in acquired immunodeficiency syndrome related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy. Cancer 2006; 106: 12835.
  • 27
    Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, Grigg R, Hylton T, Pawlish KS, McNeel TS, Goedert JJ. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123: 18794.
  • 28
    Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, Holmberg SD, Brooks JT. Incidence of types of cancer among HIV-infected Persons compared with the general population in the United States, 1992–2003. Ann Int Med 2008; 148: 72836.
  • 29
    Long JL, Engels EA, Moore RD, Gebe KA. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008; 22: 48996.
  • 30
    Achenbach CJ, Cole SR, Kitahata MM, Casper C, Willig JH, Mugavero MJ, Saag MS. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS 2011; 25: 691700.
  • 31
    The Collaboration of Observational HIV epidemiological Research Europe (COHERE) study group. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting antiretroviral therapy. AIDS 2009; 23: 202937.
  • 32
    Brenner H, Francisci S, de Angelis R, Marcos-Gragera R, Verdecchia A, Gatta G, Allemani C, Ciccoballo L, Coleman M, Sant M. Long-term survival expectations of cancer patients in Europe in 2000–2002. Eur J Cancer 2009; 45: 102841.
  • 33
    Spano JP, Costagliola D, Katlama C, Mounier C, Oksenhendler E, Khayat D. AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol 2008; 26: 483442.
  • 34
    Engels EA. Non-AIDS defining malignancies in HIV infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS 2009; 23: 87585.
  • 35
    Guiguet M, Bouè F, Coudranel J, Laug JM, Rosenthal E, Costagliela D. Effect of immunodeficiency, HIV viral load and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a perspective cohort study. Lancet Oncol 2009; 10: 115261.
  • 36
    The Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1 infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 138796.